PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11728181-0	2001	Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.	2-oxindole	0-8	cyclin dependent kinase 2	Homo sapiens	29-54	
17266627-0	2007	3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.	2-oxindole	23-31	cyclin dependent kinase 2	Homo sapiens	84-109	
17266627-0	2007	3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.	2-oxindole	23-31	cyclin dependent kinase 2	Homo sapiens	111-115	
17266627-2	2007	With the purpose of designing new chemical entities with enhanced inhibitory potencies against cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 1 (CDK1), the 3D-QSAR CoMFA study carried out on oxindole derivatives as inhibitors of these kinases is presented here.	2-oxindole	205-213	cyclin dependent kinase 2	Homo sapiens	95-120	
17266627-2	2007	With the purpose of designing new chemical entities with enhanced inhibitory potencies against cyclin dependent kinase 2 (CDK2) and cyclin dependent kinase 1 (CDK1), the 3D-QSAR CoMFA study carried out on oxindole derivatives as inhibitors of these kinases is presented here.	2-oxindole	205-213	cyclin dependent kinase 2	Homo sapiens	122-126	
15012993-0	2004	A new series of potent oxindole inhibitors of CDK2.	2-oxindole	23-31	cyclin dependent kinase 2	Homo sapiens	46-50	
15012993-1	2004	A novel series of oxindole-type inhibitors of CDK2 that have heteroatom substituted alkynyl moieties at their C-4 position is described.	2-oxindole	18-26	cyclin dependent kinase 2	Homo sapiens	46-50	
18307332-5	2008	The performance of GANDI is tested on cyclin-dependent kinase 2 (CDK2) using a library of about 14 000 fragments and the binding mode of a known oxindole inhibitor to bias the design.	2-oxindole	145-153	cyclin dependent kinase 2	Homo sapiens	38-63	
18307332-5	2008	The performance of GANDI is tested on cyclin-dependent kinase 2 (CDK2) using a library of about 14 000 fragments and the binding mode of a known oxindole inhibitor to bias the design.	2-oxindole	145-153	cyclin dependent kinase 2	Homo sapiens	65-69	
12659774-0	2003	Synthesis of potent oxindole CDK2 inhibitors.	2-oxindole	20-28	cyclin dependent kinase 2	Homo sapiens	29-33	
12659774-1	2003	A series of oxindole CDK2 inhibitors was synthesized.	2-oxindole	12-20	cyclin dependent kinase 2	Homo sapiens	21-25	
11728181-0	2001	Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.	2-oxindole	0-8	cyclin dependent kinase 2	Homo sapiens	56-60	
11728181-1	2001	Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).	2-oxindole	31-39	cyclin dependent kinase 2	Homo sapiens	181-206	
11728181-1	2001	Two closely related classes of oxindole-based compounds, 1H-indole-2,3-dione 3-phenylhydrazones and 3-(anilinomethylene)-1,3-dihydro-2H-indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).	2-oxindole	31-39	cyclin dependent kinase 2	Homo sapiens	208-212	
35623140-0	2022	Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies.	2-oxindole	30-42	cyclin dependent kinase 2	Homo sapiens	75-79	
33327806-0	2021	Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3beta inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies.	2-oxindole	6-14	cyclin dependent kinase 2	Homo sapiens	52-56	
33327806-1	2021	The serine/threonine protein kinases CDK2 and GSK-3beta are key oncotargets in breast cancer cell lines, therefore, in the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3beta inhibitors targeting breast cancer (5a-g, 7a-h, and 13a-b).	2-oxindole	153-161	cyclin dependent kinase 2	Homo sapiens	37-41	
33327806-1	2021	The serine/threonine protein kinases CDK2 and GSK-3beta are key oncotargets in breast cancer cell lines, therefore, in the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3beta inhibitors targeting breast cancer (5a-g, 7a-h, and 13a-b).	2-oxindole	153-161	cyclin dependent kinase 2	Homo sapiens	219-223	
33327806-8	2021	The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2 and Asp133 and Val135, respectively, in GSK-3beta.	2-oxindole	4-12	cyclin dependent kinase 2	Homo sapiens	176-180